Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients

Trial Profile

Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 25 Aug 2015 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov.
    • 25 Aug 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top